US 12,128,023 B2
Pharmaceutical composition containing B-lapachone as active ingredient for prevention or treatment of cholestatic liver disease
Joo Seog Yoon, Suwon-si (KR); Kang Sik Seo, Ansan-si (KR); Jeong Su Han, Suwon-si (KR); Sung Je Moon, Daejeon (KR); Jung Hoon Lee, Suwon-si (KR); and Soo Bin Yoon, Suwon-si (KR)
Assigned to CUROME BIOSCIENCES CO., LTD., Cheongju-si (KR)
Filed by CUROME BIOSCIENCES CO., LTD., Cheongju-si (KR)
Filed on Sep. 12, 2022, as Appl. No. 17/942,505.
Application 17/942,505 is a continuation of application No. 17/724,262, filed on Apr. 19, 2022.
Application 17/942,505 is a continuation of application No. PCT/KR2021/013732, filed on Oct. 6, 2021.
Claims priority of application No. 10-2020-0130028 (KR), filed on Oct. 8, 2020.
Prior Publication US 2023/0055593 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A01N 37/00 (2006.01); A01N 25/00 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 31/215 (2006.01); A61K 31/24 (2006.01); A61K 31/352 (2006.01); A61K 38/00 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 38/005 (2013.01); A61P 1/16 (2018.01)] 8 Claims
 
1. A method for prevention of treatment of cholestatic liver disease, comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition containing β-lapachone or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the cholestatic liver disease is at least one selected from the group consisting of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), and wherein the β-lapachone is administered at a dose of 20 mg/kg/day to 500 mg/kg/day.